A Three-Part Positron Emission Tomography Study of Brain CGRP Receptor Occupancy Levels Following Administration of MK-0974, Using [11C]MK-4232 as an Imaging Agent

Trial Profile

A Three-Part Positron Emission Tomography Study of Brain CGRP Receptor Occupancy Levels Following Administration of MK-0974, Using [11C]MK-4232 as an Imaging Agent

Completed
Phase of Trial: Phase I

Latest Information Update: 24 Jun 2017

At a glance

  • Drugs Telcagepant (Primary)
  • Indications Migraine
  • Focus Adverse reactions; Pharmacodynamics
  • Sponsors Merck Sharp & Dohme
  • Most Recent Events

    • 22 Aug 2011 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 15 Jul 2011 Additional lead trial centre identified as reported by ClinicalTrials.gov.
    • 15 Jul 2011 Planned End Date changed from 1 Jul 2011 to 1 Sep 2011 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top